Sofinnova Partners Closes €82 Million Sofinnova MD Start IV Fund, Oversubscribed, to Bring Out the Next Generation of Companies Medtech
9 Articles
9 Articles
The new fund strengthens a twenty-year history of Sofinnova in the creation of new companies, with resources to launch from six to eight new realities in Europe and the United States (ANSA)
(Teleborsa) - Sofinnova Partners, a leading European venture capital company in the field of life sciences with offices in Paris, London and Milan, today announced the final closure of the Sofinnova Fund...
Sofinnova Partners closes oversubscribed €82 million MD Start IV fund to build new MedTech startups
Sofinnova Partners, a Paris-based life sciences investor, has closed its Sofinnova MD Start IV fund at €82 million. The firm said the fund was oversubscribed and will build on a strategy dating back to 2008 that has created around a dozen companies. “Sofinnova MD Start is one of the few strategies in Europe focused on […]
Sofinnova Partners Closes Oversubscribed €82 Million Sofinnova MD Start IV Fund to Create the Next Generation of Medtech Companies – Novumpr
The new fund extends Sofinnova’s 20-year track record of company creation with capacity to launch six to eight new ventures across Europe and the US PARIS–(BUSINESS WIRE)– Sofinnova Partners (“Sofinnova”), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova MD Start IV at […]
MD Start IV closes beyond the target of €82 million, which is 30% more than the previous year. This new fund will focus, among other things, on the cardiovascular and women's health.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
